Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pulse Biosciences, Inc - Common Stock (NQ:PLSE)

26.94 +1.95 (+7.80%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 640,655
Open 25.54
Bid (Size) 26.97 (100)
Ask (Size) 28.47 (200)
Prev. Close 24.99
Today's Range 25.02 - 28.53
52wk Range 12.56 - 27.98
Shares Outstanding 54,902,942
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Pulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences CEO Bought 15,000 Company Shares. Here's What That Means for Investors. ↗
Pulse Biosciences, a developer of non-thermal bioelectric treatments, reported a notable insider buy amid recent stock price gains. 
Via The Motley Fool
Topics Regulatory Compliance

Performance

YTD
+101.2%
+101.2%
1 Month
+34.5%
+34.5%
3 Month
+48.8%
+48.8%
6 Month
+99.7%
+99.7%
1 Year
+52.8%
+52.8%

More News

Read More
News headline image
ATM Equity Purchases by Pulse Biosciences’ Co-Chairmen Total Approximately $13.3 Million
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Q1 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
Pulse Biosciences Inc (NASDAQ:PLSE) Narrows Q4 Loss, Beats Revenue Estimates ↗
Via Chartmill
News headline image
PLSE Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
Pulse Biosciences to Present at the BofA Securities 2026 Healthcare Conference
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences (PLSE) Q1 2025 Earnings Transcript ↗
Via The Motley Fool
News headline image
PLSE Q4 2025 Earnings Transcript ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Pulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Presents Positive Outcomes in Late-Breaking Updated Data from nPulse™ Cardiac Catheter System at Heart Rhythm 2026
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences’ nPulse™ Technology to be Featured at the Heart Rhythm Society 2026 Annual Meeting
From Pulse Biosciences
Via Business Wire
News headline image
Pulse Biosciences to Host Analyst Event on April 25, 2026
From Pulse Biosciences
Via Business Wire
News headline image
Pulse Biosciences Strengthens Executive Leadership Team
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Enrolls First Patients in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences to Present at the 25th Annual Needham Virtual Healthcare Conference
From Pulse Biosciences, Inc
Via Business Wire
News headline image
Pulse Biosciences Announces Strategic Alignment to Accelerate Cardiac Catheter Program Following Exceptional Long-Term AFib Clinical Data
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences, Inc. Announces First Enrollments in Feasibility Study for the Treatment of Malignant Thyroid Tumors with nPulse™ Technology
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Announces Clinical Data From nPulse™ Vybrance™ System First-In-Human Clinical Durability Study of Benign Thyroid Nodule Ablation
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences to Present at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences’ nPulse™ Vybrance™ System to be Featured in Multiple Presentations at the North American Society for Interventional Thyroidology Meeting
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences to Present at the 46th Annual TD Cowen Healthcare Conference
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2025 Financial Results
From Pulse Biosciences, Inc.
Via Business Wire
These stocks have an unusual volume in today's session ↗
Via Chartmill

Frequently Asked Questions

Is Pulse Biosciences, Inc - Common Stock publicly traded?
Yes, Pulse Biosciences, Inc - Common Stock is publicly traded.
What exchange does Pulse Biosciences, Inc - Common Stock trade on?
Pulse Biosciences, Inc - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Pulse Biosciences, Inc - Common Stock?
The ticker symbol for Pulse Biosciences, Inc - Common Stock is PLSE on the Nasdaq Stock Market
What is the current price of Pulse Biosciences, Inc - Common Stock?
The current price of Pulse Biosciences, Inc - Common Stock is 26.94
When was Pulse Biosciences, Inc - Common Stock last traded?
The last trade of Pulse Biosciences, Inc - Common Stock was at 06/04/26 04:00 PM ET
What is the market capitalization of Pulse Biosciences, Inc - Common Stock?
The market capitalization of Pulse Biosciences, Inc - Common Stock is 1.48B
How many shares of Pulse Biosciences, Inc - Common Stock are outstanding?
Pulse Biosciences, Inc - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.